Sphere Fluidics
Latest round
- Series A
Last raised
- Oct 2021
Total raised
- $24M
Investors
- 2
About Sphere Fluidics
Sphere Fluidics Limited, founded in 2010 in Cambridge, UK, develops single-cell analysis systems and has pivoted its offerings towards advanced microfluidic technologies.122 mn.Sphere Fluidics specializes in advanced single-cell analysis and isolation technologies, primarily utilizing their proprietary picodroplet microfluidic technology. Their core offerings include the Cyto-Mine® platform, which streamlines antibody discovery and cell line development processes, enabling researchers to identify high-producing, viable clones with increased efficiency and confidence. The company’s detection kits, such as the Cyto-Cellect® range, provide sensitive, animal-origin free assays for measuring cell clone productivity and detecting mouse IgG antibodies, catering to applications in biologics discovery, cell engineering, and synthetic biology.Sphere Fluidics operates on a business-to-business model, generating revenue primarily through the sale of its Cyto-Mine® platform and associated reagents, consumables, and assay kits. The revenue model encompasses direct sales of products to research institutions and biopharmaceutical companies, as well as potential subscription-based support services that offer continued access to product updates and technical assistance. Transactions typically involve bulk purchases of consumables, with clients placing orders based on their specific project requirements. Flagship products such as the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit are integral to their sales strategy, facilitating ongoing engagements with customers seeking to enhance their laboratory workflows and outcomes. The company is expected to design and launch new products targeting advancements in single-cell analysis, with plans to expand into new markets and geographic regions including Europe and the Asia-Pacific region in the near future.
Who invested in Sphere Fluidics
2 investors across 1 round
See all investors in Sphere Fluidics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 15, 2021
Amount
$24M
Investors
Questions about Sphere Fluidics
Who invested in Sphere Fluidics?
Sphere Fluidics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sphere Fluidics raised?
Sphere Fluidics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Sphere Fluidics last raise money?
Sphere Fluidics's most recent round on record is a Series A, in Oct 2021.
What does Sphere Fluidics do?
Sphere Fluidics Limited, founded in 2010 in Cambridge, UK, develops single-cell analysis systems and has pivoted its offerings towards advanced microfluidic technologies.
Where is Sphere Fluidics headquartered?
Sphere Fluidics is headquartered in Cambridge, UK.
Which VCs invest in companies like Sphere Fluidics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Sphere Fluidics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Sphere Fluidics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.